Drugs / ARC-521
last change Nov 2016 re-read 2 minutes ago

ARC-521

Developed for
hepatitis B virus infection
Investigated by
Arrowhead Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02797522 Jun → Nov 2016 hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ARC-521 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02797522